RT info:eu-repo/semantics/article
T1 Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study
A1 Martín Arias, Luis Hermenegildo
A1 Treceño Lobato, Carlos
A1 García Ortega, María Pilar
A1 Rodríguez Paredes, Juan
A1 Escudero, Antonio
A1 Sáinz Gil, María
A1 Salado Valdivieso, María Inés
A1 Velasco González, Verónica
A1 Carvajal García-Pando, Alfonso
K1 Osteoporosis - Tratamiento farmacológico
AB Introduction Bisphosphonates are used worldwide to treatosteoporosis and, thus, to prevent fractures. Though theyhave been proven in clinical trials to avoid some fractures,their effectiveness in reducing hip fractures is unclear. Theaim of the present study was to explore the relationshipbetween bisphosphonate use and hip fracture trends inSpain.Methods For this purpose, an ecologic study spanning 2002to 2008 was conducted in Spain. Consumption data wereobtained from the Spanish Ministry of Health and SocialPolicy. The number of hip fractures was obtained fromhospital discharges; annual hip fracture rates were determinedand standardized using the Spanish 2002 populationcensus. A linear regression was performed between fracturerate and use of bisphosphonates; R2 and Pearson correlationcoefficient were calculated.Results From 2002 to 2008, dispensed prescriptions ofbisphosphonates in Spain increased from 3.28 to 17.66DDD/1,000 inhabitants per day. In the same period, thecrude hip fracture rate increased from 2.85 to 3.02 casesper 1,000 inhabitants older than 50 years; however, whenage standardized rates were estimated, the rate declinedfrom 2.85 to 2.79. Analyzed by sex, the standardized ratefor men slightly increased from 1.45 to 1.48, while forwomen the rate significantly dropped from 4.00 to 3.91.Conclusion A small effect of bisphosphonates on hip fracturerates can not be ruled out; however, other factors mightpartially explain this decline. Assuming this medication wasthe only cause for hip fracture rate reduction, the elevatedmedication cost to avoid a single hip fracture makes itnecessary to explore less expensive interventions
PB Springer Verlag
SN 0031-6970
YR 2013
FD 2013
LK http://uvadoc.uva.es/handle/10324/8601
UL http://uvadoc.uva.es/handle/10324/8601
LA eng
NO European journal of clinical pharmacology, 2013, vol. 69, no 3, p. 559-564.
NO Producción Científica
DS UVaDOC
RD 04-dic-2024